CAJ | 학술논문

目的探讨同种异基因骨髓腔内骨髓移植(IBM-BMT)对小鼠早期造血功能重建的影响.方法将BALB/c小鼠骨髓单个核细胞(BMNCs)分别用胫骨骨髓腔内注射(IBMI)和尾静脉注射(IV)两种方法移植入经致死量~(60)Coγ射线辐照后的60只C57BL/6小鼠.受鼠随机分为3组:骨髓腔内注射高和低剂量组(IBM1和IBM2组)、尾静脉注射组(IV组),每组20只.在骨髓移植后1、3、6和9 d分别计数各组受鼠胫骨骨髓腔内有核细胞总数,并用流式细胞术检测供体植入水平(供体来源有核细胞总数、供体来源髓系细胞数).结果于移植后6 d,IBM1组和IBM2组注射侧胫骨骨髓腔内有核细胞总数、供体来源有核细胞总数、供体来源髓系细胞总数均明显高于IV组(P<0.05或P<0.01).结论 IBM-BMT较IV-BMT更能促进同种异基因骨髓移植后的早期造血功能重建.
목적 탐토동충이기인골수강내골수이식(IBM-BMT)대소서조기조혈공능중건적영향.방법 장BALB/c소서골수단개핵세포(BMNCs)분별용경골골수강내주사(IBMI)화미정맥주사(IV)량충방법이식입경치사량~(60)Coγ사선복조후적60지C57BL/6소서.수서수궤분위3조:골수강내주사고화저제량조(IBM1화IBM2조)、미정맥주사조(IV조),매조20지.재골수이식후1、3、6화9 d분별계수각조수서경골골수강내유핵세포총수,병용류식세포술검측공체식입수평(공체래원유핵세포총수、공체래원수계세포수).결과 우이식후6 d,IBM1조화IBM2조주사측경골골수강내유핵세포총수、공체래원유핵세포총수、공체래원수계세포총수균명현고우IV조(P<0.05혹P<0.01).결론 IBM-BMT교IV-BMT경능촉진동충이기인골수이식후적조기조혈공능중건.
Objective To investigate the effects of allogenic intra-bone marrow bone marrow transplantation (IBM-BMT) on re-establishing hematopoiesis in mice. Methods Bone marrow mononuclear cells (BMNCs) from BALB/ c mice were transplanted into the C57BL/6 mice treated with a lethal dose of ~(60)Coγ-ray radiation through intra-bone marrow injection or intravenous injection. Sixty of the C57BL/6 mice were randomly divided into three groups as higher dose intra-bone marrow injection group (IBM1 group), lower dose intra-bone marrow injection group (IBM2 group) and intravenous injection group (IV group). The nucleated cell numbers of whole bone marrow from the tibia of each recipient mouse were counted respectively at the day 1, day 3, day 6 and day 9 after the transplantation. The donor-derived total nucleated cells and myeloid cells were quantified by flow cytometry. Results At 6th day after transplantation, more total bone marrow nucleated cells, total donor-derived nucleated cells and donor-derived myeloid cells in the tibia of injected side in both IBM1 group and IBM2 group were found than that in IV group (P<0.05 or P<0.01). Conclusion Compared with traditional bone marrow transplantation (IV-BMT),IBM-BMT improves the bone marrow hematopoiesis in the early hematopoietic re-establishing stage in allogenic bone marrow transplantation.